Transient impairment of the adaptive response to fasting in FXR-deficient mice  by Cariou, Bertrand et al.
FEBS Letters 579 (2005) 4076–4080 FEBS 29740Transient impairment of the adaptive response to fasting
in FXR-deﬁcient mice
Bertrand Carioua, Kirsten van Harmelena, Daniel Duran-Sandovala, Theo van Dijkb,
Aldo Grefhorstb, Emmanuel Bouchaerta, Jean-Charles Frucharta, Frank J. Gonzalezc,
Folkert Kuipersb, Bart Staelsa,*
a Research Unit 545 INSERM, Atherosclerosis Department, Pasteur Institute of Lille, Faculty of Pharmacy, Lille2 University, Lille, France
b Center for Liver, Digestive and Metabolic Diseases, Laboratory of Pediatrics, University Hospital, Groningen, The Netherlands
c Laboratory of Metabolism, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States
Received 16 June 2005; accepted 17 June 2005
Available online 1 July 2005
Edited by Robert BaroukiAbstract The farnesoid X receptor (FXR) has been suggested
to play a role in gluconeogenesis. To determine whether FXR
modulates the response to fasting in vivo, FXR-deﬁcient
(FXR/) and wild-type mice were submitted to fasting for
48 h. Our results demonstrate that FXR modulates the kinetics
of alterations of glucose homeostasis during fasting, with
FXR/ mice displaying an early, accelerated hypoglycaemia re-
sponse. Basal hepatic glucose production rate was lower in
FXR/ mice, together with a decrease in hepatic glycogen con-
tent. Moreover, hepatic PEPCK gene expression was transiently
lower in FXR/mice after 6 h of fasting and was decreased in
FXR/hepatocytes. FXR therefore plays an unexpected role
in the control of fuel availability upon fasting.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Gluconeogenesis1. Introduction
Farnesoid X receptor (FXR) is a nuclear receptor that is
activated by bile acids (BAs) and is mainly expressed in liver,
intestine, kidney and adrenal glands. A major role of FXR is
to protect liver cells from the deleterious eﬀect of BA overload
by decreasing their endogenous production and by accelerating
BA biotransformation and cellular excretion [1]. The demon-
stration that FXR-deﬁcient mice display elevated serum levels
of triglycerides and HDL-cholesterol has highlighted a critical
role of FXR in lipid metabolism also [2].
More recently, several studies have suggested that FXR
might also regulate carbohydrate metabolism [3]. The ﬁrst
indication for a potential role of FXR in diabetes came from
the observation that hepatic FXR expression is reduced in ani-
mal models of diabetes [4]. Moreover, hepatic FXR expression
is induced in response to fasting via the action of the peroxi-Abbreviations: BA, bile acid; FXR, farnesoid X receptor; FFA, free
fatty acid; F1-6 biPase, fructose 1,6-bis phosphatase; G6Pase, glucose-
6-phosphatase; HGP, hepatic glucose production; L-CPT-1, liver-type
carnitine palmitoyltransferase 1; PPARa, peroxisome proliferator-
activated receptor a; PEPCK, phosphoenolpyruvate carboxykinase;
PGC-1a, PAR-c coactivator-1a; SHP, small heterodimer partner
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doi:10.1016/j.febslet.2005.06.033some proliferator-activated receptor (PPAR)-c coactivator-1a
(PGC-1a), suggesting that FXR activation might participate
in the induction of gluconeogenesis [5]. In accordance with this
hypothesis, a recent report indicated that FXR activation by
BAs or the non-steroidal FXR-speciﬁc synthetic agonist
GW4064 results in an increased gene expression of the key glu-
coneogenic enzyme phosphoenolpyruvate carboxykinase
(PEPCK) in vitro in rat and human hepatocytes, as well as
in vivo in mouse liver [6]. In contrast, several other studies re-
ported that BA treatment decreases gene expression of PEPCK
as well as other gluconeogenic genes such as glucose-6-phos-
phatase (G6Pase) and fructose 1,6-bis phosphatase (F1-6 bi-
Pase) [7–9]. Therefore, the exact contribution of FXR in the
control of hepatic glucose metabolism remains unclear.
To study the physiological role of FXR in vivo in the control
of glucose homeostasis upon fasting, the kinetics of response
to fasting was studied in FXR-deﬁcient and wild-type mice.
Our results show that FXR-deﬁcient mice exhibit an initial
transient hypoglycaemia due to an impaired hepatic glucose
production (HGP). These ﬁndings identify a new, physiologi-
cal function for FXR in the adaptive response to fasting.2. Materials and methods
2.1. Fasting protocol
Homozygous FXR/ female mice of 12–14 weeks of age and gen-
der- and age-matched wild type mice (FXR+/+) bred on the C57BL6/
N genetic background have been described previously [2]. FXR+/+
and FXR/ mice were fasted during 6 and 48 h with free access to
water. Tail vein blood samples were taken for blood glucose measure-
ments (Accu-Chek Active\). Orbital blood samples were taken for plas-
ma metabolite measurements. Mice were sacriﬁced and livers were
removed, immediately frozen in liquid N2 and stored at 80 C until
further analysis.
2.2. Analytical procedures
Blood metabolites were measured using the following kits: insulin
(Mercodia AB), triglycerides, total cholesterol and HDL-cholesterol
(Roche), FFAs (WAKO), b-hydroxybutyrate (Randox), lactate
(Sigma). Hepatic glycogen content was measured as previously
described [10].
2.3. Primary hepatocytes
Hepatocytes were isolated from the livers of fed mice by a modiﬁca-
tion of the collagenase method [11]. Hepatocytes were cultured in ser-
um-free Williams E medium (Invitrogen) supplemented with 2 mmol/l
glutamine, 25 lg/ml gentamicine, 100 nmol/l dexamethasone, 0.1%ation of European Biochemical Societies.
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humidiﬁed atmosphere of 5% CO2, 95% air. After cell attachment
(6 h), medium was changed to glucose-free Dulbeccos modiﬁed Eagles
medium (Invitrogen) supplemented with 2 mmol/l glutamine, 25 lg/ml
gentamicine, 100 nmol/l dexamethasone, and 5 mmol/l D-glucose, and
cells were treated either with GW4064 (Genﬁt) (5 lmol/L) or DMSO
for 24 h.
2.4. Hepatic glucose production rate
Hepatic glucose production rate was measured in FXR/ and
FXR+/+ mice after 9 h of fasting. The experiment was performed in
chronically catheterised, freely moving animals as described before
[10]. Mice received a continuous infusion of 2.5 mg/ml of [6,6-2H2]-glu-
cose at a rate of 0.6 ml/h, which resulted in an input rate of
4.9 ± 0.4 lmol/kg/min.
The hepatic glucose production rate was calculated over the steady
state period between 3 and 5 h after the start of the experiment by iso-
tope dilution as
RaðGlcÞ ¼ ðMPEðGlc;M2Þinfusate=MPEðGlc;M2Þblood  1Þ
 infusionðGlc;M2Þ
in which MPE(Glc;M2)infusate is the mole percent enrichment of infused
[6,6-2H2]-glucose, MPE(Glc;M2)blood is the mole percent enrichment
measured in bloodspots and infusion (Glc;M2) is the infusion rate of
[6,6-2H2]-glucose.
2.5. Real time quantitative RT-PCR
RNA (3 lg) was reverse transcribed, and cDNA was quantiﬁed by
real-time quantitative PCR on a MX4000 apparatus (Stratagene) using
the speciﬁc primers (Eurogentec, SA), as described previously [4]:
Primers used for quantitative real-time PCRGene Sequences (50–30)PEPCK Forward AGCCTCGACAGCCTGCCCCAGGReverse CCAGTTGTTGACCAAAGGCTTTTSHP Forward ACTGGCTGCAGTTCAGTGGCReverse GCACATCGGGGTTGAAGAGGG6Pase Forward GAAGGCCAAGAGATGGTGTGAReverse TGCAGCTCTTGCGGTACATGF1-6 biPase Forward CACAGCTCTATGGTATCGCTReverse AGAACACAGGTAGCGTAGGAPPARa Forward AGGCCGTTGCCACTGTTCAGReverse AGCCCTCTTCATCCCCAAGCPGC-1a Forward TTCTGGGTGGATTGAAGTGGTGReverse TGTCAGTGCATCAAATGAGGGCL-CPT-1 Forward CATCATGACTATGCGCTACTCReverse CAGTGCTGTCATGCGTTGG36B4 Forward CATGCTCAACATCTCCCCCTTCTCCReverse GGGAAGGTGTAATCCGTCTCCACAG2.6. Statistical analysis
Statistical signiﬁcance was analysed using the unpaired Students t
test. All values are reported as means ± S.E.M. Values of P < 0.05
were considered signiﬁcant.3. Results
3.1. FXR-deﬁciency in mice leads to transient hypoglycaemia
upon fasting
Metabolic adaptation to prolonged fasting was examined
in FXR/and FXR+/+ female mice. Similar results werefound in age-matched male mice (data not shown). Weight
loss was similar in both strains (Fig. 1A). While there was
no diﬀerence in the fed state, blood glucose levels dropped
more rapidly in FXR/ than in FXR+/+ mice after initia-
tion of fasting, with values statistically lower at 3 h
(153 ± 4 vs. 122 ± 4 mg/dl; FXR+/+ and FXR/, respec-
tively, P < 0.001) and 6 h (146 ± 4 vs. 125 ± 3 mg/dl;
P < 0.001). In contrast, blood glucose levels did not diﬀer
after 24 and 48 h of fasting between both strains (Fig.
1B). Blood insulin levels were signiﬁcantly lower at 6 h of
fasting in FXR/ mice, following the drop of glycaemia
(Fig. 1C). Plasma b-hydroxybutyrate concentration was
greatly increased during fasting in FXR+/+ mice. A similar
proﬁle was observed in FXR/ mice, except for a signiﬁ-
cantly higher value after 6 h of fasting (Fig. 1D). As previ-
ously reported [12], circulating free fatty acid (FFA) levels
were signiﬁcantly higher in FXR/ mice in the fed state.
This diﬀerence in FFA was still observed after 6 h of fasting,
whereas there were no diﬀerences between both genotypes
upon long-term fasting (Fig. 1E). Finally, plasma lactate
concentrations, which mainly reﬂect the rate of glycolysis
in muscle, exhibited a similar proﬁle during fasting in both
strains, except for a lower value after 24 h of fasting in
FXR/ mice (Fig. 1F).
To determine whether the hypoglycaemia observed during
the early phase of fasting in FXR/ mice is due to a decreased
hepatic glucose output, endogenous glucose production was
measured after 9 h of fasting. HGP was signiﬁcantly lower in
FXR/than in FXR+/+ mice in the basal state. In contrast,
HGP was suppressed to a similar extent by insulin in both
groups during a hyperinsulinemic euglycemic clamp study
(Fig. 2B), indicating that hepatic insulin sensitivity was not al-
tered in FXR/ mice.3.2. Hepatic glycogen content is reduced in FXR/ mice
Both glycogenolysis and gluconeogenesis contribute to
HGP. Since the hypoglycaemia occurred within 3 h after
food withdrawal, we next investigated whether glycogen
metabolism is altered in FXR/ mice. Hepatic glycogen
content of FXR/ mice was only 50% of the level in
FXR+/+ mice in the fed state (P < 0.05), and only 45% after
6 h of fasting (P < 0.05). Hepatic glycogen was almost com-
pletely depleted in both genotypes after 24 h of fasting
(Fig. 3).3.3. FXR-deﬁciency leads to a decreased PEPCK mRNA
expression both in vivo in mouse liver and in vitro in primary
mouse hepatocytes
Next, the expression of genes encoding various enzymes
and transcription factors involved in the regulation of
HGP was analyzed in the livers of FXR+/+ and FXR/
mice. Since diﬀerences in blood glucose levels were maximal
during the early time course of fasting, mRNA levels were
measured after 6 h of fasting. The expression of PEPCK
was signiﬁcantly lower (P < 0.001) in livers of FXR/ com-
pared to mice (Table 1). In contrast, the expression of both
G6Pase and F1-6biPase did not diﬀer between both geno-
types, even though G6Pase mRNA levels tended to be de-
creased in FXR/ mice (P = 0.07). PGC-1a mRNA levels
were similar in both genotypes. Moreover, gene expression
of peroxisome proliferator-activated receptor a (PPARa)
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Fig. 1. Diﬀerences in metabolic parameters between FXR+/+ and FXR/ mice upon fasting. FXR+/+ and FXR/ mice were fasted during 48 h and
plasma samples were taken at 0 h (n = 23), 3 h (n = 10), 6 h (n = 23), 24 h (n = 23) and 48 h (n = 5). (A) Weight loss presented as percentage of initial
body weight. (B) Blood glucose concentrations (mg/dl). (C) Plasma insulin concentrations (lg/l). (D) Plasma b-hydroxybutyrate concentrations
(mmol/l). (E) Plasma FFA concentrations (mmol/l) and (F) Plasma lactate concentrations (mg/dl). Data are the pool of three independent experiment
and are presented as means ± S.E.M. \P < 0.05, \\P < 0.01, \\\P < 0.001 signiﬁcantly diﬀerent from FXR+/+ mice.
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(L-CPT-1) did not diﬀer between FXR+/+ and FXR/ mice,
suggesting that FXR controls hepatic PEPCK gene expres-
sion in vivo via a PPARa-independent pathway.
To assess the direct role of FXR in the regulation of hepatic
PEPCK gene expression, PEPCK mRNA levels were measured
in isolated hepatocytes from FXR/ and FXR+/+ mice. FXR-
deﬁciency resulted in a 58% decrease (P < 0.05) in basal
PEPCK mRNA levels. The activation of FXR by its non-ste-
roidal speciﬁc agonist GW4064 did not alter PEPCK gene
expression in both FXR+/+and FXR/ hepatocytes (Fig.
4A). In the same conditions, mRNA levels of the small hetero-
dimer partner (SHP), a well-characterized FXR target gene,
was increased by more than 6-fold (P < 0.001) in primary
hepatocytes from FXR+/+ mice, whereas there was no change
in FXR/ mice (Fig. 4B). Altogether, these data indicate that
PEPCK gene expression is regulated by FXR in mouse
hepatocytes under basal, but not under agonist-stimulated
condition.4. Discussion
In the present study, we investigated the metabolic conse-
quences resulting from FXR-deﬁciency in mice upon fasting.
Our results conﬁrm that FXR plays a role in the regulation
of hepatic carbohydrate metabolism, since FXR/ mice are
hypoglycaemic and display a decreased HGP upon short-term
fasting. Previous studies have mainly focused on the regulation
of PEPCK gene expression by FXR agonists with conﬂicting
results [3]. Our ﬁndings support the hypothesis of a functional
positive regulation of PEPCK mRNA expression by FXR. In
primary mouse hepatocytes FXR-deﬁciency strongly decreases
basal PEPCKmRNA levels, suggesting that FXR expression is
necessary for maintaining basal hepatic PEPCK expression in
vitro. However, the previously described induction of PEPCK
expression by the speciﬁc FXR-agonist GW4064 reported in
primary rat hepatocytes [6] was not observed in mouse hepato-
cytes. While a species-speciﬁc diﬀerence in regulation cannot be
excluded, it should be noted that the reported level of PEPCK
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Fig. 4. Basal PEPCK mRNA levels are decreased in hepatocytes from
FXR/ mice. PEPCK (A) and SHP (B) mRNA levels in primary
FXR+/+ and FXR/ mouse hepatocytes, treated with the FXR
agonist GW4064 (5 lM) or DMSO for 24 h, were measured by
quantitative real-time PCR. Values are normalized relative to 36B4
mRNA and are expressed (means ± S.E.M.) relative to those of FXR+/+
mice treated with DMSO, which are arbitrarily set at 1. Statistical
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Fig. 2. Endogenous glucose production is decreased in FXR/ mice
after short-term fasting. Basal (left panel) and insulin-clamped (right
panel) endogenous glucose production (lmol/kg/min) was measured as
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Fig. 3. Hepatic glycogen content in FXR/ mice is decreased in both
the fed state and after short-term fasting. Liver glycogen content was
assessed as described in Section 2. Glycogen content of FXR+/+ and
FXR/ mice is expressed as means ± S.E.M., \P < 0.05 statistically
diﬀerent from control mice (n = 46 mice/group).
Table 1
Hepatic PEPCK mRNA levels are decreased in FXR/ mice after
short-term fasting
Gene FXR+/+ FXR/ Statistics
Gluconeogenesis
PEPCK 100 ± 8% 40 ± 7% P < 0.001
G6Pase 100 ± 14% 63 ± 10% P = 0.07
F1.6biPase 100 ± 18% 100 ± 27% NS
PGC-Ia 100 ± 14% 72 ± 17% NS
b-oxidation
PPARa 100 ± 23% 123 ± 24% NS
CPT-I 100 ± 22% 143 ± 30% NS
mRNA levels of genes involved in HGP were measured in livers of
FXR+/+ and FXR/ mice after 6 h of fasting. Values are normalized
relative to 36B4 mRNA levels and are expressed (means ± S.E.M.)
relative to those of FXR+/+ mice, which are arbitrarily set at 1 (n = 6
mice/group).
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induced PEPCK expression under the same conditions
(approximately 1.5–2-fold vs. 20-fold, respectively) [7]. In a
more physiological setting, we found that hepatic PEPCK
expression is decreased in FXR/mice after 6 h of fasting,
without statistically signiﬁcant changes in the expression of
other gluconeogenic enzymes. We recently demonstrated that
PEPCKmRNA expression in FXR/mice returned to similar
levels as controls after 24 h of fasting [12], indicating that FXR
preferentially regulates the kinetics rather than the amplitude of
PEPCK expression. In accordance with this latter observation,
PEPCK mRNA levels did not diﬀer between both genotypes
after 48 h of fasting (data not shown), showing that the adaptive
response to long-term fasting is still preserved in FXR/mice.
In an opposite manner, PEPCK gene expression is also more
4080 B. Cariou et al. / FEBS Letters 579 (2005) 4076–4080rapidly down-regulated upon high-carbohydrate refeeding in
FXR/ than in wild type mice [12]. Thus, FXR appears to
act as a molecular modulator of PEPCK expression during
nutritional changes. In this context, it should be pointed out
that FXR expression increases 6 h after the initiation of fasting
(data not shown).
Since PEPCK is thought to be a rate-controlling enzyme of
gluconeogenesis [13], one might anticipate that the observed
hypoglycaemia in 6 h fasted FXR/ mice is directly linked
to impaired hepatic gluconeogenesis. However, the phenotype
of PEPCK-deﬁcient mice prompts for moderation of this con-
clusion. While mice that totally lack PEPCK die within 3 days
of birth from hypoglycaemia, mice with liver-speciﬁc PEPCK-
deﬁciency were shown to be able to maintain euglycaemia dur-
ing fasting, delineating the existence of multiple compensatory
mechanisms that may act at both intra- and extrahepatic levels
[14–16]. In this way, it is noteworthy that FXR is highly ex-
pressed in the kidney and the intestine, two other gluconeogenic
organs. However, data about a functional role of FXR in glu-
cose homeostasis in such tissues are currently lacking.
Although the relative contribution of gluconeogenesis and
glycogenolysis to HGP remains uncertain, it is widely accepted
that short-term induction of HGP upon fasting mainly reﬂects
induction of glycogenolysis [17]. Thus, the decrease in blood
glucose levels as early as 3 h after the initiation of fasting
may implicate an impaired glycogenolysis in FXR/ mice.
In accordance with this hypothesis, hepatic glycogen stores
were found to be reduced in post-absorptive and more rapidly
depleted in fasted FXR/ mice. Underlying molecular mech-
anisms could implicate a defect in glycogen synthesis, altered
kinetics of glycogen mobilization or both. Hepatic mRNA
expression of glycogen synthase and glycogen phosphorylase,
two key enzymes of glycogen metabolism, did not diﬀer be-
tween FXR+/+ and FXR/ mice (data not shown), indicating
that variation in the expression levels of these enzymes cannot
explain the diﬀerences between both genotypes. Additional
studies with metabolic ﬂux measurements in vivo in the livers
of these mice are currently underway to elucidate this issue.
In conclusion, this study provides new evidence for a role of
FXR in the regulation of glucose homeostasis. While the long-
term fasting adaptation response is not altered by FXR-
deﬁciency, the absence of FXR alters the kinetics of metabolic
changes during short-term fasting, accelerating the drop of
glycaemia. Therefore, FXR appears to play an unexpected role
in carbohydrate metabolism, a function that opens exciting
perspectives for the understanding of the pathophysiology of
metabolic disorders, such as type 2 diabetes and obesity.
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